New hope for Platinum-Resistant ovarian cancer: BL-M07D1 enters phase 3 trial
NCT ID NCT07545460
First seen Jun 26, 2026 · Last updated Jun 30, 2026 · Updated 3 times
Summary
This Phase 3 trial compares a new drug called BL-M07D1 against standard chemotherapy in 404 people with HER2-expressing ovarian, fallopian tube, or peritoneal cancer that has become resistant to platinum-based treatment. Participants will receive either BL-M07D1 or one of several chemotherapies chosen by their doctor. The study aims to see if BL-M07D1 can delay cancer growth or improve survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BL-M07D1 (a drug given by IV every 3 weeks)
What this could lead to
If it works, this could offer a new treatment option for people with hard-to-treat ovarian cancer that has stopped responding to platinum chemotherapy.
What could go wrong
This is an early-stage Phase 3 trial, so results are not yet known. The drug may not work better than existing chemotherapies, and side effects could be significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY PERITONEAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
Contact
-
Yunnan Cancer Hospital
Kunming, Yunnan, China
Contact